‘COMBINE-2’: Real-world evidence for effectiveness of Two Drug Regimen, Antiretroviral therapy with integrase inhibitors plus a reverse transcriptase inhibitor (207859)

Study identification

• EU PAS number:
  EUPAS24990
• Study ID:
  48021
• Official title and acronym:
  ‘COMBINE-2’: Real-world evidence for effectiveness of Two Drug Regimen, Antiretroviral therapy with integrase inhibitors plus a reverse transcriptase inhibitor (207859)
• DARWIN EU® study:
  No
• Study countries:
  Belgium

  France

  Italy

  Portugal

  Spain

  United Kingdom
• Study status:
  Finalised

Research institutions and networks

Institutions

ViiV Healthcare

Multiple centres: 39 centres are involved in the study

Study timelines

Date when funding contract was signed

Planned: 20/11/2017

Actual: 20/11/2017

Study start date

Planned: 20/12/2019

Actual: 18/11/2019

Date of final study report

Planned: 31/05/2023

Actual: 30/05/2023

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

ViiV Healthcare

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  EU RMP category 3 (required)